Clinical trial
Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With…
NCT00483704 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00483704 |
|---|---|
| Title | Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) |
| Official title | A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraines |
| Intervention type | Drug |
| Interventions | Telcagepant 140 mg, Talcagepant 280 mg, Placebo |
| Enrollment | 1,935 |
| Start date | Aug 14, 2008 |
| Primary completion | Mar 25, 2009 |
| Completion | Mar 25, 2009 |
| First posted | Jun 7, 2007 |
| Last update posted | Oct 18, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: